Clinical Trials
28 trialsNCT04895709 2026-06-04
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Recruiting
NCT06851663 2026-05-29
Trop2-targeted immunoPET Imaging of Solid Tumors
RenJi Hospital
Phase 2/3 Recruiting
NCT07334119 2026-05-20
Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors
Myeloid Therapeutics
Phase 1 Recruiting
NCT07285044 2026-05-18
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Mayo Clinic
Phase 2 Recruiting
NCT04969835 2026-05-15
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
Avacta Life Sciences Ltd
Phase 1 Recruiting
NCT04977453 2026-05-15
Keynote B59
GI Innovation, Inc.
Phase 1/2 Recruiting
NCT07557225 2026-05-14
18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
Peking University First Hospital
Phase NA Recruiting
NCT05581004 2026-05-11
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Phase 1 Recruiting
NCT06270706 2026-04-20
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Pliant Therapeutics, Inc.
Phase 1 Recruiting
NCT06582017 2026-04-13
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Nammi Therapeutics Inc
Phase 1 Recruiting
NCT06695845 2026-04-09
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Jazz Pharmaceuticals
Phase 2 Recruiting
NCT06293898 2026-03-23
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
SystImmune Inc.
Phase 1 Recruiting
NCT05269381 2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2 Recruiting
NCT06047379 2026-03-02
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
Phase 1/2 Recruiting
NCT06330064 2026-02-12
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)
Daiichi Sankyo
Phase 2 Recruiting
NCT06781983 2026-01-07
Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
Innate Pharma
Phase 1 Recruiting
NCT06999187 2026-01-07
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Dren Bio
Phase 1 Recruiting
NCT06943521 2025-12-11
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Tanabe Pharma America, Inc.
Phase 1/2 Recruiting
NCT03452774 2025-10-28
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Massive Bio, Inc.
Recruiting
NCT05107674 2025-09-09
A Study of NX-1607 in Adults With Advanced Malignancies
Nurix Therapeutics, Inc.
Phase 1 Recruiting
NCT07118176 2025-08-12
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
Jonsson Comprehensive Cancer Center
Phase 1 Recruiting
NCT06967961 2025-07-29
DP-PAN-CANCER
Institut Claudius Regaud
Phase NA Recruiting
NCT05078047 2025-06-05
MOIO
UNICANCER
Phase 3 Recruiting
NCT06337084 2025-05-22
Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors
Monopar Therapeutics
Phase 1 Recruiting
NCT06617169 2025-05-21
Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors
Monopar Therapeutics
Phase 1 Recruiting
NCT04510129 2025-03-12
A Multicenter Cancer Biospecimen Collection Study
Cofactor Genomics, Inc.
Recruiting
NCT06022757 2024-02-23
KEYNOTE F19
Evopoint Biosciences Inc.
Phase 1/2 Recruiting
NCT05733000 2023-03-10
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
Northwestern University
Phase 2 Recruiting